Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+44.7%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+44.7%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
3x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$67.81M+33.9%
2024$50.64M-23.4%
2023$66.08M+195.1%
2022$22.39M-21.8%
2021$28.65M-